Zhejiang Tianyu Pharmaceutical Co Ltd (300702) - Net Assets
Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) has net assets worth CN¥3.72 Billion CNY (≈ $544.40 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.56 Billion ≈ $960.51 Million USD) and total liabilities (CN¥2.84 Billion ≈ $416.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Tianyu Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.72 Billion |
| % of Total Assets | 56.68% |
| Annual Growth Rate | 20.4% |
| 5-Year Change | -1.38% |
| 10-Year Change | 605.52% |
| Growth Volatility | 35.51 |
Zhejiang Tianyu Pharmaceutical Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Tianyu Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual net assets of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2024. For live valuation and market cap data, see 300702 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.50 Billion ≈ $511.83 Million |
+0.29% |
| 2023-12-31 | CN¥3.49 Billion ≈ $510.37 Million |
-0.21% |
| 2022-12-31 | CN¥3.50 Billion ≈ $511.43 Million |
-5.78% |
| 2021-12-31 | CN¥3.71 Billion ≈ $542.77 Million |
+4.58% |
| 2020-12-31 | CN¥3.55 Billion ≈ $519.00 Million |
+74.10% |
| 2019-12-31 | CN¥2.04 Billion ≈ $298.10 Million |
+40.84% |
| 2018-12-31 | CN¥1.45 Billion ≈ $211.66 Million |
+12.33% |
| 2017-12-31 | CN¥1.29 Billion ≈ $188.43 Million |
+112.03% |
| 2016-12-31 | CN¥607.31 Million ≈ $88.87 Million |
+22.50% |
| 2015-12-31 | CN¥495.77 Million ≈ $72.55 Million |
+8.67% |
| 2014-12-31 | CN¥456.22 Million ≈ $66.76 Million |
+0.56% |
| 2013-12-31 | CN¥453.68 Million ≈ $66.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Tianyu Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 649.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.67 Billion | 47.73% |
| Common Stock | CN¥347.98 Million | 9.95% |
| Other Comprehensive Income | CN¥-6.66 Million | -0.19% |
| Other Components | CN¥1.49 Billion | 42.51% |
| Total Equity | CN¥3.50 Billion | 100.00% |
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Tianyu Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Norion Bank
ST:NORION
|
$1.07 Billion |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
$1.07 Billion |
|
Donnelley Financial Solutions Inc
NYSE:DFIN
|
$1.08 Billion |
|
ZINKA LOGISTICS SOL LTD
NSE:BLACKBUCK
|
$1.08 Billion |
|
Guardian Capital Group Ltd. Cl.A Nv (GCG-A.TO
TO:GCG-A
|
$1.07 Billion |
|
Goosehead Insurance Inc
NASDAQ:GSHD
|
$1.07 Billion |
|
PennyMac Mortgage Investment Trust
NYSE:PMT
|
$1.07 Billion |
|
Prosiebensat 1 Media AG
XETRA:PSM
|
$1.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Tianyu Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,487,771,350 to 3,497,773,912, a change of 10,002,562 (0.3%).
- Net income of 55,935,072 contributed positively to equity growth.
- Dividend payments of 70,193,741 reduced retained earnings.
- Share repurchases of 27,785,487 reduced equity.
- Other comprehensive income decreased equity by 6,519,500.
- Other factors increased equity by 58,566,218.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥55.94 Million | +1.6% |
| Dividends Paid | CN¥70.19 Million | -2.01% |
| Share Repurchases | CN¥27.79 Million | -0.79% |
| Other Comprehensive Income | CN¥-6.52 Million | -0.19% |
| Other Changes | CN¥58.57 Million | +1.67% |
| Total Change | CN¥- | 0.29% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Tianyu Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.33x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.86 | CN¥21.09 | x |
| 2014-12-31 | CN¥1.90 | CN¥21.09 | x |
| 2015-12-31 | CN¥2.05 | CN¥21.09 | x |
| 2016-12-31 | CN¥2.51 | CN¥21.09 | x |
| 2017-12-31 | CN¥4.93 | CN¥21.09 | x |
| 2018-12-31 | CN¥4.47 | CN¥21.09 | x |
| 2019-12-31 | CN¥6.22 | CN¥21.09 | x |
| 2020-12-31 | CN¥10.90 | CN¥21.09 | x |
| 2021-12-31 | CN¥10.69 | CN¥21.09 | x |
| 2022-12-31 | CN¥10.11 | CN¥21.09 | x |
| 2023-12-31 | CN¥10.20 | CN¥21.09 | x |
| 2024-12-31 | CN¥10.01 | CN¥21.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Tianyu Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.13%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.88x
- Recent ROE (1.60%) is below the historical average (9.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 7.40% | 4.64% | 0.74x | 2.14x | CN¥-11.78 Million |
| 2014 | 5.29% | 3.11% | 0.72x | 2.38x | CN¥-21.48 Million |
| 2015 | 10.16% | 5.99% | 0.63x | 2.68x | CN¥777.62K |
| 2016 | 20.14% | 11.30% | 0.71x | 2.49x | CN¥61.61 Million |
| 2017 | 7.78% | 8.43% | 0.56x | 1.64x | CN¥-28.58 Million |
| 2018 | 11.31% | 11.16% | 0.56x | 1.82x | CN¥19.02 Million |
| 2019 | 28.75% | 27.75% | 0.74x | 1.39x | CN¥382.01 Million |
| 2020 | 18.81% | 25.78% | 0.53x | 1.38x | CN¥312.39 Million |
| 2021 | 5.52% | 8.04% | 0.44x | 1.56x | CN¥-166.25 Million |
| 2022 | -3.40% | -4.46% | 0.42x | 1.84x | CN¥-468.37 Million |
| 2023 | 0.78% | 1.08% | 0.40x | 1.82x | CN¥-321.42 Million |
| 2024 | 1.60% | 2.13% | 0.40x | 1.88x | CN¥-293.84 Million |
Industry Comparison
This section compares Zhejiang Tianyu Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Tianyu Pharmaceutical Co Ltd (300702) | CN¥3.72 Billion | 7.40% | 0.76x | $1.07 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical … Read more